Dr. Levy’s role is to manage the synthetic process development of PRV-001 with the goal to optimize the process for yield and manufacturing cost. He received his academic degrees from the University of California – Berkeley (B.S., 1987) and the Massachusetts Institute of Technology (Ph.D., 1992). Since 1992, Dr. Levy worked in the biopharmaceutical industry designing novel treatments for indications which included: Cancer, Inflammation, Multiple Sclerosis, Alzheimer’s Disease, Deep Vein Thrombosis, Congestive Heart Failure, & Arrhythmia.
Dr. Levy has extensive experience in all aspects of organic and medicinal chemistry. Through his efforts, Dr. Levy designed and developed the syntheses for novel chemical entities from various chemical and pharmaceutical classes.
Having worked at companies of all sizes, Dr. Levy was most recently the Director of Synthetic Chemistry at Intradigm Corporation pursuing delivery vehicles for siRNA therapeutics. Previous employers include Glycomed Inc., COR Therapeutics and Scios, Inc.